HomeCONGRESS

CONGRESS

View Category
Day 3

ASTRONAUT: Aliskiren failed to show benefits in patients with acute heart failure

Hospitalization for heart failure, (HF), represents a major health problem with high rates of death or early...
solaci -
Learn More
Day 3

RELAX Study: Phosphodieserase-5 inhibitors showed no benefit in heart failure with preserved ventricular function.

Phosphodieserase-5 enzyme is activated in heart failure and can limit the beneficial effects of nitric oxide, (NO),...
solaci -
Learn More
Day 3

STOP-HF: The use of B-type natriuretic peptide (BNP) for screening high-risk population decreases the prevalence of heart failure

B-type natriuretic peptide (BNP) can be a reliable marker for the diagnosis of heart failure (HF). This...
solaci -
Learn More
Day 3

PRAGUE-6: off-pump versus in-pump CABG in high-risk patients

Coronary artery bypass grafting (CABG) without a cardiopulmonary bypass, (CBP), has increasingly become an alternative to the...
solaci -
Learn More
SOLACI Session

Endovascular theraphy for acute and critical limb ischemia

Felix Damas De Los Santos2013-03-10
solaci -
Learn More
SOLACI Session

The Role of the Interventional Cardiologist in the Treatment of Venous Disease

Oscar Mendiz 2013-03-09
solaci -
Learn More
Day 2

Possible benefit for patients with acute myocardial infarction but without ventricular dysfunction.

Background: To evaluate whether the administration of eplerenone 24 hours after an acute myocardial infarction (AMI) in...
solaci -
Learn More
Day 2

SELECT ACS: The Inclacumab seems to reduce myocardial injury post angioplasty

P-selectin is an adhesion molecule involved in the interactions between endothelial cells, platelets and leukocytes. Inclacumab is...
solaci -
Learn More